Adipotide

Adipotide (Proapoptotic Vascular Targeting Peptide — CKGGRAKDC-GG-KLAKLAKKLAKLAK)

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

An investigational preclinical peptide whose approved evidence is bounded to obese rhesus-macaque work. The study’s renal-toxicity signal is a material limit on translation, and there is no human interventional evidence.

Plain English

Researchers study Adipotide in the context of an obese rhesus-macaque experiment. Its findings cannot establish human efficacy, safety, or dosing, and the renal-toxicity signal in that work is a material translational limitation.

Overview

Adipotide is an experimental chimeric peptidomimetic designed to target white-adipose vasculature. The approved source describes findings in obese monkeys, including weight loss and renal toxicity; it does not establish human efficacy, safety, or a clinical development pathway.

Research Summary

The canonical study is a nonhuman-primate experiment. Its results, including the reported renal safety signal, are preclinical and cannot be translated into a human dose or therapeutic conclusion.

Research Areas

  • Adipose vascular targeting
  • Novel obesity mechanisms
  • Prohibitin biology
  • Body composition research
  • Experimental weight loss

Safety & Risks

Serious Risks

  • Renal toxicity in the obese rhesus-macaque study is a material translational limitation.
  • No human interventional evidence or human safety profile is established.

Reported Side Effects

  • Renal toxicity observed in the obese rhesus-macaque study.
United States
Investigational preclinical peptide; not FDA-approved.
United Kingdom
Investigational preclinical peptide; not FDA-approved.
Australia
Investigational preclinical peptide; not FDA-approved.
Canada
Investigational preclinical peptide; not FDA-approved.

Citations & Sources